Climb Bio, Inc. (CLYM) stock
CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.78−0.16 (-1.61%)
Close on Nov 17, 2026Market cap $561.73MP/E –Yield –
Climb Bio operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Climb Bio's operating cash flow for the twelve months ending Jun 30, 2026 was -$52.70M. For fiscal 2025 it was -$54.36M. The highest annual figure on record is -$14.10M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$54.36M | – |
| FY2024 | Dec 31, 2024 | -$15.56M | – |
| FY2023 | Dec 31, 2023 | -$20.60M | – |
| FY2022 | Dec 31, 2022 | -$37.37M | – |
| FY2021 | Dec 31, 2021 | -$36.07M | – |
| FY2020 | Dec 31, 2020 | -$14.10M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.55M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.38M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.64M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.14M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.15M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.43M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.52M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.56M | -316.5% |
| Q2 FY2024 | Jun 30, 2024 | -$667.00K | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.82M | – |
| Q4 FY2023 | Dec 31, 2023 | -$947.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $3.49M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.97M | – |
| Q1 FY2023 | Mar 31, 2023 | -$15.18M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.45M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.18M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.97M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.78M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.88M | – |
| Q3 FY2021 | Sep 30, 2021 | -$12.97M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.48M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.74M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.62M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.38M | – |
See a number that looks wrong?